Understand the source comparison
SS-31 Results Timeline: Dosing and Administration Comparison
The SS-31 results timeline varies based on dosing frequency, route of administration, and cumulative exposure duration. Understanding how these variables shift the timeline is essential for protocol design and outcome interpretation. Daily subcutaneous (1–5 mg
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The SS-31 results timeline varies based on dosing frequency, route of administration, and cumulative exposure duration. Understanding how these variables shift the timeline is essential for protocol design and outcome interpretation.
- Daily subcutaneous (1–5 mg/kg)
- Measurable ATP increase, 25–35% ROS reduction within 48h
- Mitophagy activation, 40–60% increase in functional mitochondria by week 6
- Sustained tissue-level improvements, structural remodeling visible by week 12–16
- Gold standard for research. Consistent plasma levels maintain cardiolipin binding throughout observation window
- Intermittent dosing (3× weekly)
- Comparable acute biochemical effects per dose
- Slower intermediate progression. Mitophagy improvements delayed by ~2 weeks vs daily
- Long-term outcomes achievable but require extended timelines (16–20 weeks vs 12–14 weeks daily dosing)
- Suitable for chronic models where cumulative exposure matters more than peak concentration
- Single-dose or short-term (1–7 days)
- Acute ATP and ROS improvements measurable but transient. Return to baseline within 48h of final dose
- No sustained mitophagy activation; mitochondrial population does not shift toward healthier phenotype
- No long-term structural or functional improvements
- Useful only for acute injury models (ischemia-reperfusion) where immediate protection is the endpoint
- High-dose bolus (10+ mg/kg)
- No additional acute benefit vs 3–5 mg/kg. Cardiolipin binding saturates at lower concentrations
- Potential for off-target effects without improved timeline acceleration
- Not studied in long-term protocols; no evidence of safety or efficacy beyond 5 mg/kg
- Higher doses do not compress the SS-31 results timeline. Mitochondrial turnover rate is the limiting factor, not peptide availability
- The rate-limiting step in the SS-31 results timeline is mitochondrial turnover, not drug availability. Increasing dose above the threshold required for complete cardiolipin binding does not accelerate mitophagy, biogenesis, or tissue repair. Those processes operate on biological timelines (days to weeks) that no dosing strategy can bypass. Researchers attempting to compress timelines through dose escalation consistently fail because the biology does not permit faster progression.